QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Schold, S. C. Articles by Prados, M. D. Search for Related Content PubMed PubMed Citation

O⁶-Benzylguanine suppression of O⁶-alkylguanine-DNA alkyltransferase in anaplastic gliomas

University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232 (S.C.S); Departments of Neurological Surgery (D.M.K.) and Neurology (K.L.F.), The University of Texas Southwestern Medical Center, Dallas, TX 75390; Departments of Neurological Surgery (S.M.C., M.S.B., M.D.P.) and Pathology (R.L.D.), University of California at San Francisco, San Francisco, CA 94143; Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 (K.R.H.); Division of Neuro-Oncology, University of Virginia, Charlottesville, VA 22908 (D.S.); Department of Medicine, Medical Oncology Section, University of Wisconsin, Madison, WI 53792 (H.I.R.); Department of Human Oncology, University of Wisconsin Medical School, Madison, WI 53792 (M.P.M.); USA

² Address correspondence to S. Clifford Schold Jr., University of Pittsburgh Cancer Institute, 5150 Centre Ave., Room 433, Pittsburgh, PA 15232 (cschold{at}hs.pitt.edu).

Abstract

The purpose of the study was to determine the dose of O⁶-benzylguanine (BG) that would suppress O⁶-alkylguanine-DNA alkyltransferase (AGT) activity to undetectable levels in >90% of anaplastic gliomas, as measured 6 h after a 1-h BG infusion. Subjects who were scheduled for surgical resection of a known or presumed anaplastic glioma received a 1-h infusion of BG. Tumor tissue was surgically removed approximately 6 h after the end of the infusion and was analyzed for AGT activity. The BG dose was escalated until at least 11 of 14 subjects had no detectable AGT activity. An additional cohort of patients received the identified effective dose of BG approximately 18 h before tumor resection in order to compare our results with an earlier study using the longer time interval. In the 79 subjects who were enrolled, there was no significant toxicity that was attributed to the BG. A dose-response relationship was determined between the BG dose and the percentage of subjects with undetectable AGT. A dose of 120 mg/m² suppressed AGT to less than detectable levels in 17 of 18 patients when the drug-resection interval was 6 h. With an 18-h interval, only 5 of 11 subjects had undetectable AGT at the 120-mg/m² dose. We conclude that a BG dose of 120 mg/m² given 6 h before an alkylating drug would be effective in suppressing AGT and possibly potentiating the cytotoxic effects of the drug.

References

Baer, J.C., Freeman, A.A., Newlands, E.S., Watson, A.J., Rafferty, J.A., and Margison, G.P. (1993) Depletion of O⁶-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer 67,1299 -1302.[ISI][Medline]

Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J., Alas, L., Li, B., Citron, M., Wasserman, P., White, A., Eyre, H., Jaeckle, K., Schulman, S., Rector, D., Prados, M., Coons, S., Shapiro, W., and Yarosh, D. (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 56,783 -788.[Abstract/Free Full Text]

Bocangel, D.B., Finkelstein, S., Schold, S.C., Bhakat, K.K., Mitra, S., and Kokkinakis, D.M. (2002) Multifaceted resistance of gliomas to temozolomide. Clin. Cancer Res. 8,2725 -2734.[Abstract/Free Full Text]

Dolan, M.E., and Pegg, A.E. (1997) O⁶-Benzylguanine and its role in chemotherapy. Clin. Cancer Res. 3,837 -847.[Abstract]

Felker, G.M., Friedman, H.S., Dolan, M.E., Moschel, R.C., and Schold, C. (1993) Treatment of subcutaneous and intracranial brain tumor xenografts with O⁶-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol. 32,471 -476.[CrossRef][ISI][Medline]

Friedman, H.S., Kokkinakis, D.M., Pluda, J., Friedman, A.H., Cokgor. I., Haglund, M.M., Ashley, D.M., Rich. J., Dolan, M.E., Moschel, R.C., McLendon, R.E., Kerby, T., Herndon, J.E., Bigner, D.D., and Schold, S.C., Jr. (1998) Phase I trial of O⁶-benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. 16,3570 -3575.[Abstract]

Friedman, H.S., Pluda, J., Quinn, J.A., Ewesuedo, R.B., Long, L., Friedman, A.H., Cokgor, I., Colvin, O.M., Haglund, M.M., Ashley, D.M., Rich, J.N., Sampson, J., Pegg, A.E., Moschel, R.C., McLendon, R.E., Provenzale, J.M., Stewart, E.S., Tourt-Uhlig, S., Garcia-Turner, A.M., Herndon, J.E. 2nd, Bigner, D.D., and Dolan, M.E. (2000) Phase I trial of carmustine plus O⁶-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 18,3522 -3528.[Abstract/Free Full Text]

Jaeckle, K.A., Eyre, H.J., Townsend, J.J., Schulman, S., Knudson, H.M., Belanich, M., Yarosh, D.B., Bearman, S.I., Giroux, D.J., and Schold, S.C. (1998) Correlation of tumor O⁶-methylguanine-DNA methyltransferase levels with the survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study. J. Clin. Oncol. 16,3310 -3315.[Abstract]

Kokkinakis, D.M., Bocangel, D.B., Schold, S.C., Moschel, R.C., and Pegg, A.E. (2001) Thresholds of O⁶-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin. Cancer Res. 7,421 -428.[Abstract/Free Full Text]

Kokkinakis, D.M., Moschel, R.C., Pegg, A.E., and Schold, S.C. (1999) Eradication of human medulloblastoma tumor xenografts with a combination of O⁶-benzyl-2'-deoxyguanosine and 1,3-bis(2chloroethyl)1-nitrosourea. Clin. Cancer Res. 5,3676 -3681.[Abstract/Free Full Text]

Kokkinakis, D.M., Moschel, R.C., Vuong, T.H., Reddy, M.V., Schold, S.C., and Pegg, A.E. (1996) Mechanism of depletion of O⁶-methylguanine-DNA methyltransferase activity in rat tissues by O⁶-benzyl-2'-deoxyguanosine. Role of metabolism. In Vivo 10,297 -306.[Medline]

Long, L., and Dolan, M.E. (2001) Role of cytochrome P450 isoenzymes in metabolism of O⁶-benzylguanine: Implications for dacarbazine activation. Clin. Cancer Res. 7,4239 -4244.[Abstract/Free Full Text]

Quinn, J.A., Pluda, J., Dolan, M.E., Delaney, S., Kaplan, R., Rich, J.N., Friedman, A.H., Reardon, D.A., Sampson, J.H., Colvin, O.M., Haglund, M.M., Pegg, A.E., Moschel, R.C., McLendon, R.E., Provenzale, J.M., Gururangan, S., Tourt-Uhlig, S., Herndon, J.E. 2nd, Bigner, D.D., and Friedman, H.S. (2002) Phase II trial of carmustine plus O⁶-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20,2277 -2283.[Abstract/Free Full Text]

Roy, S.K., Korzekwa, K.R., Gonzalez, F.J., Moschel, R.C., and Dolan, M.E. (1995) Human liver oxidative metabolism of O⁶-benzylguanine. Biochem. Pharmacol. 50,1385 -1389.[CrossRef][ISI][Medline]

Schilsky, R.L., Dolan, M.E., Bertucci, D., Ewesuedo, R.B., Vogelzang, N.J., Mani, S., Wilson, L.R., and Ratain, M.J. (2000) Phase I clinical and pharmacological study of O⁶-benzylguanine followed by carmustine in patients with advanced cancer. Clin. Cancer Res. 6,3025 -3031.[Abstract/Free Full Text]

Schold, S.C., Jr., Brent, T.P., von Hofe, E., Friedman, H.S., Mitra, S., Bigner, D.D, Swenberg, J.A., and Kleihues, P. (1989) O⁶-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J. Neurosurg. 70,573 -577.[ISI][Medline]

Spiro, T.P., Gerson, S.L., Liu, L., Majka, S., Haaga, J., Hoppel, C.L., Ingalls, S.T., Pluda, J.M., and Willson, J.K. (1999) O⁶-Benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res. 59,2402 -2410.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick, M. Weller, M. P. Mehta, and M. R. Gilbert Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity J. Clin. Oncol., September 1, 2008; 26(25): 4189 - 4199. [Abstract] [Full Text] [PDF]

				S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, P. Y. Wen, H. A. Fine, M. P. Mehta, L. M. DeAngelis, F. S. Lieberman, et al. Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium Neuro-oncol, August 1, 2008; 10(4): 631 - 642. [Abstract] [Full Text] [PDF]

				A. Broniscer, S. Gururangan, T. J. MacDonald, S. Goldman, R. J. Packer, C. F. Stewart, D. Wallace, M. K. Danks, H. S. Friedman, T. Y. Poussaint, et al. Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report Clin. Cancer Res., November 15, 2007; 13(22): 6712 - 6718. [Abstract] [Full Text] [PDF]

				J. Weingart, S. A. Grossman, K. A. Carson, J. D. Fisher, S. M. Delaney, M. L. Rosenblum, A. Olivi, K. Judy, S. B. Tatter, and M. E. Dolan Phase I Trial of Polifeprosan 20 With Carmustine Implant Plus Continuous Infusion of Intravenous O6-Benzylguanine in Adults With Recurrent Malignant Glioma: New Approaches to Brain Tumor Therapy CNS Consortium Trial J. Clin. Oncol., February 1, 2007; 25(4): 399 - 404. [Abstract] [Full Text] [PDF]

				A. Chakravarti, M. G. Erkkinen, U. Nestler, R. Stupp, M. Mehta, K. Aldape, M. R. Gilbert, P. McL. Black, and J. S. Loeffler Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms Clin. Cancer Res., August 1, 2006; 12(15): 4738 - 4746. [Abstract] [Full Text] [PDF]

				K. E. Warren, A. A. Aikin, M. Libucha, B. C. Widemann, E. Fox, R. J. Packer, and F. M. Balis Phase I Study of O6-Benzylguanine and Temozolomide Administered Daily for 5 Days to Pediatric Patients With Solid Tumors J. Clin. Oncol., October 20, 2005; 23(30): 7646 - 7653. [Abstract] [Full Text] [PDF]

				J. A. Quinn, A. Desjardins, J. Weingart, H. Brem, M. E. Dolan, S. M. Delaney, J. Vredenburgh, J. Rich, A. H. Friedman, D. A. Reardon, et al. Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma J. Clin. Oncol., October 1, 2005; 23(28): 7178 - 7187. [Abstract] [Full Text] [PDF]

				M. S. Bobola, J. R. Silber, R. G. Ellenbogen, J. R. Geyer, A. Blank, and R. D. Goff O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines Clin. Cancer Res., April 1, 2005; 11(7): 2747 - 2755. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Schold, S. C. Articles by Prados, M. D. Search for Related Content PubMed PubMed Citation